Heart Failure
Conditions
Keywords
Chronic Heart Failure, Natriuretic Peptides, Cenderitide
Brief summary
Planned enrollment is approximately twelve subjects with stable chronic heart failure. Enrolled subjects will receive up to eight sequential days of continuous, stepwise, dose increasing, subcutaneous (SQ) infusions of open-label cenderitide via the Insulet Drug Delivery System. Planned infusion rates of cenderitide will be administered to subjects continuously during four, 48-hour infusion periods.
Interventions
DRUGCenderitide
Cenderitide is a dual receptor natriuretic peptide.
Sponsors
Capricor Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Male or female, ≥ 18 years of age * Body Mass Index (BMI) of 18-40 kg/m2, inclusive * Current or historical New York Heart Association (NYHA) functional class ≥ II * At least one of the following: documented systolic heart failure with an ejection fraction (EF) ≤ 40% and/or a historical measurement of plasma BNP ≥ 150 pg/mL (or NT-proBNP ≥ 600 pg/mL) * Systolic blood pressure 100-160 mmHg * Stable and compliant treatment with oral heart failure medications for at least 4 weeks prior to Screening Key
Exclusion criteria
* Known hypersensitivity or allergy to natriuretic peptide or its components, nesiritide, other natriuretic peptides or related compounds * Current clinical diagnosis of acute decompensated heart failure (ADHF) * Clinical diagnosis of acute coronary syndrome (ACS) within 30 days prior to Screening. * Symptomatic postural hypotension * Evidence of uncorrected volume or sodium ≤ 130 mmol/L or other condition that would predispose the patient to adverse events * Clinically significant aortic or mitral valve stenosis * Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (not including restrictive mitral filling patterns) * Severe renal failure defined as creatinine clearance \< 45 mL/min as estimated by either the Cockcroft-Gault or the MDRD equations * Significant pulmonary disease (e.g., history of oral daily steroid dependency, history of Carbon Dioxide (CO2) retention or need for intubation for acute exacerbation, or currently receiving IV steroids) * Known hepatic impairment as indicated by any of the following: A) total bilirubin \> 3 mg/dL; B) albumin \< 2.8 mg/dL, with other signs or symptoms of hepatic dysfunction; C) increased ammonia levels, if performed, with other signs or symptoms of hepatic dysfunction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability as assessed by changes in vital signs (blood pressure, heart rate, and body temperature), clinical laboratory tests, adverse events, 12-lead ECGs, and physical examinations compared to pre-dose, baseline measurements. | Measurements performed at regular intervals on Days 1-10, and at the safety follow-up visit (Day 16 ± 2 days). |
| Pharmacokinetic (PK) profile of cenderitide as measured in area under the blood concentration-curve (AUC) from time zero to 48 hours post each infusion rate start, maximum blood concentration (Cmax), and time of maximum blood concentration (Tmax). | PK blood collection at regular intervals on Days 1-10. |
| Pharmacodynamic (PD) response as assessed by changes in blood pressure, heart rate, weight, fluid balance (intake/output), plasma cGMP, ANP, NT-proBNP, and aldosterone, and urine cGMP compared to pre-dose baseline assessments. | PD assessments performed at regular intervals on Days 1-10, and at the safety follow-up visit (Day 16 ± 2 days). |
Countries
United States
Outcome results
None listed